DME in 2016: A Review of Treatment Guidelines and the Role o -

The live program has concluded.

If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.

Scroll back to top

Details

Overview
This continuing medical education (CME) activity captures content from roundtable discussion held in June 2016. This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.Jointly provided by Evolve Medical Education LLC, New Retina MD, and Retina Today. Supported through an educational grant by Regeneron Pharmaceuticals.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Assess the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF therapies for common retinal diseases, including DME
- Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations
- Develop plans to initiate treatment for conditions, such as DME, using anti-VEGF agents, as well as better understand when to change therapeutic strategies
Accreditation
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, Retina Today and New Retina MD.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Charles C. Wykoff, MD, PhD, moderator Retina Consultants of Houston, Blanton Eye Institute Houston, Texas
Caroline R. Baumal, MD New England Eye Center Boston, Massachusetts
David Eichenbaum, MD Retina Vitreous Associates of Florida Tampa, Florida
Chirag P. Shah, MD, MPH Ophthalmic Consultants of Boston Boston, Massachusetts
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical
Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Charles C. Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Bayer Pharmaceuticals; Clearside Biomedical; DORC International; Genentech; ONL Therapeutics; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Acucela; Alcon; Allegro Ophthalmics LLC; Allergan; Ampio Pharmaceuticals; Apellis Pharmaceuticals; Clearside Biomedical; Genentech; Iconic Therapeutics; Ophthotech Corporation; pSivida Corp.; Regeneron Pharmaceuticals; Roche Pharma; Santen Pharmaceutical Co., Ltd.; ThromboGenics NV; and XOMA Ltd.
Caroline R. Baumal, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board/Speaker’s Bureau: Allergan; and Genentech.
David Eichenbaum, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Genentech; Ophthotech Corporation; and Regeneron Pharmaceuticals. Grant/Research Support: Alcon; Alimera Sciences; Allergan; Genentech; Ophthotech Corporation; and River Vision. Stock/Shareholder: Hemera Biosciences; and US Retina.
Chirag P. Shah, MD, MPH, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Genentech; and Regeneron Pharmaceuticals.
Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Emily Feinman, administrator, New Retina MD and Retina Today; Michelle Dalton, writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, New Retina MD, Retina Today, or Regeneron Pharmaceuticals.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 09/30/2017